GlassScriptPhysician profile
Stephen Petrofsky
NPI 1821051160
$5,372.77
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,382 · 2020: $328 · 2021: $261 · 2022: $385 · 2023: $287 · 2024: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470 · Travel and Lodging: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.80 |
| Travel and Lodging | $546.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,976.22 | 2019-2022 | |
| Convatec INC. | $1,117.80 | 2024 | |
| Organogenesis INC. | $578.47 | 2019-2024 | Puraply |
| Aroa Biosurgery Incorporated | $382.14 | 2024 | |
| Wright Medical Technology, INC. | $266.04 | 2019-2020 | |
| Horizon Therapeutics Plc | $209.65 | 2019-2021 | |
| Ossio INC | $151.68 | 2024 | |
| Linvatec Corporation | $134.23 | 2023 | Colink 2, In2bones USA, Quantum |
| Pacira Pharmaceuticals Incorporated | $124.99 | 2020 | |
| Depuy Synthes Products, INC. | $119.27 | 2023 | Fibergraft Bg Morsels, Fibergraft Aeridyan Matrix |
| Paratek Pharmaceuticals, INC. | $115.00 | 2022 | |
| Melinta Therapeutics, LLC | $112.12 | 2019 | |
| Arthrosurface Incorporated | $28.26 | 2019 | |
| Kci USA, INC. | $23.43 | 2019 | |
| Smith+Nephew, INC. | $20.64 | 2024 | Grafix Pl |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Petrofsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.